Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07089784 · ClinicalTrials.gov registry record · Phase 1

Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)

A Phase 1 study of Diabetes Mellitus, Type 2, sponsored by Merck Sharp & Dohme.

Recruiting
Registry status
Phase 1
Development phase
64
Enrollment target
11
Study locations

NCT07089784 is a Phase 1 study of Diabetes Mellitus, Type 2 that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 64 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 11 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07089784, a Phase 1 study of Diabetes Mellitus, Type 2, is actively recruiting participants, sponsored by Merck Sharp & Dohme.

RECRUITING
Registry status
Phase 1
Development phase
64 participants
Enrollment target
11
Study locations

Study Summary

The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-2828. The study will also measure what happens to MK-2828 in the body of a person with type 2 diabetes (T2D) over time (pharmacokinetic or PK study), and how it affects the amount of high-sensitivity C-reactive protein (hsCRP) in a person's blood.

Conditions Studied

Diabetes Mellitus, Type 2

Interventions

  • DRUG Placebo
  • DRUG MK-2828

Study Locations (11)

Florida

  • Velocity Clinical Research, Hallandale Beach ( Site 0010) - Hallandale
  • Jacksonville Center for Clinical Research ( Site 0002) - Jacksonville
  • Advanced Pharma CR, LLC ( Site 0001) - Miami
  • QPS Miami Research Associates ( Site 0005) - South Miami

California

  • ProSciento Inc. ( Site 0004) - Chula Vista
  • California Clinical Trials Medical Group managed by PAREXEL ( Site 0008) - Glendale

Missouri

  • Alliance for Multispecialty Research, LLC ( Site 0013) - Kansas City
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0009) - Springfield

Kentucky

  • AMR Lexington ( Site 0012) - Lexington

Tennessee

  • AMR Clinical ( Site 0003) - Knoxville

Texas

  • ICON Early Phase Services ( Site 0006) - San Antonio

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2025-09-22
Est. Completion 2026-06-29
Phase Phase 1

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07089784

The ClinicalTrials.gov registry entry for NCT07089784 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07089784 reports 11 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Missouri.

Frequently Asked Questions

What is clinical trial NCT07089784 about?

NCT07089784 is a clinical study titled "Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)". The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-2828. The study will also measure what happens to MK-2828 in the body of a person with type 2 diabetes (T2D) over time (pharmacokinetic or PK study), and how it affects the amount of high-sensiti...

What is the current status of trial NCT07089784?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2025-09-22. Estimated completion is 2026-06-29.

What conditions does trial NCT07089784 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.

What interventions are being tested in trial NCT07089784?

The interventions under investigation include: Placebo (DRUG), MK-2828 (DRUG).

Who is sponsoring clinical trial NCT07089784?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07089784 being conducted?

This trial has 11 study locations across California, Florida, Kentucky, Missouri, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetes Mellitus, Type 2

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.